Alexandra joined Angelini Ventures as an Investor in September 2026. Prior to joining Angelini Ventures, she spent two years at Sofinnova Partners' Crossover team, investing in therapeutics and medical devices and supporting the investment in Neurent Medical. Before Sofinnova, she was at Ysios Capital, where she worked on investments in Neurona Therapeutics (acquired by UCB), Repronovo, and Engrail Therapeutics. Alexandra holds a PhD from UCL in vascular biology and an MSc in Bioengineering from Imperial College London.